During the corresponding time, Ovid Therapeutics Inc saw a revenue deteriorated by -88.31 % year on year, While revenue at the Ovid Therapeutics Inc 's corporate clients
Ovid Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers and third-party payors in the healthcare sector, including private third-party payors, Medicare, Medicaid, and other federal healthcare programs. Its operations involve healthcare providers, health plans, healthcare clearinghouses, and their business associates engaged in delivering or paying for healthcare benefits, items, or services. The healthcare professionals referenced include physicians such as doctors, dentists, optometrists, podiatrists, chiropractors, as well as physician assistants, nurse practitioners, and teaching hospitals. The company operates in federal, state, and foreign healthcare markets subject to various healthcare regulations.
Ovid Therapeutics Reveals Promising Pre-Clinical Outcomes for OV329: Absence of Accumulation in Animal Retinas Contrasts with Vigabatrin NEW YORK, Sept. 26, 2024 - Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to enhancing the lives of individuals afflicted by rare epilepsies and brain disorders, has unveiled the results of a pivotal pre-clinical study. This study investigated whether OV329, a GABA-aminotransferase (GABA-AT) inhibitor, accumulates in the mouse retina and brain, comparing its profile with vigabatrin (VGB), the sole FDA-approved GABA-AT inhibitor.The head-to-head study revealed a significant distinction: OV329 did not exhibit the accumulation in the retinas of ...
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to advancing treatments for rare epilepsies and brain conditions, in collaboration with Graviton Bioscience Corporation, a clinical-stage biotechnology company focusing on innovative therapeutic compounds, have reported promising results from their recent Phase 1 clinical trial. The trial assessed the safety, tolerability, and pharmacokinetic (PK) profile of the OV888/GV101 capsule, a potential first-in-class therapy for cerebral cavernous malformations (CCM). Phase 1 Clinical Trial ResultsThe Phase 1 study involved healthy volunteers and was designed to investigate the safety and tolerability of multiple ascending doses of OV888...
Ovid Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers and third-party payors in the healthcare sector, including private third-party payors, Medicare, Medicaid, and other federal healthcare programs. Its operations involve healthcare providers, health plans, healthcare clearinghouses, and their business associates engaged in delivering or paying for healthcare benefits, items, or services. The healthcare professionals referenced include physicians such as doctors, dentists, optometrists, podiatrists, chiropractors, as well as physician assistants, nurse practitioners, and teaching hospitals. The company operates in federal, state, and foreign healthcare markets subject to various healthcare regulations.
Sources:
Ovid Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ovid Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Ovid Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %